Heparin‐binding epidermal growth factor‐like growth factor as a novel targeting molecule for cancer therapy

HB‐EGF, a member of the EGF family of growth factors, exerts its biological activity through activation of the EGFR and other ErbB receptors. HB‐EGF participates in diverse biological processes, including heart development and maintenance, skin wound healing, eyelid formation, blastocyst implantation, progression of atherosclerosis and tumor formation, through the activation of signaling molecules downstream of ErbB receptors and interactions with molecules associated with HB‐EGF. Recent studies have indicated that HB‐EGF gene expression is significantly elevated in many human cancers and its expression level in a number of cancer‐derived cell lines is much higher than those of other EGFR ligands. Several lines of evidence have indicated that HB‐EGF plays a key role in the acquisition of malignant phenotypes, such as tumorigenicity, invasion, metastasis and resistance to chemotherapy. Studies in vitro and in vivo have indicated that HB‐EGF expression is essential for tumor formation of cancer‐derived cell lines. CRM197, a specific inhibitor of HB‐EGF, and an antibody against HB‐EGF are both able to inhibit tumor growth in nude mice. These results indicate that HB‐EGF is a promising target for cancer therapy, and that the development of targeting tools against HB‐EGF could represent a novel type of therapeutic strategy, as an alternative to targeting ErbB receptors. (Cancer Sci 2006; 97: 341–347)

[1]  T. Uchida,et al.  Mutation in the structural gene for diphtheria toxin carried by temperate phage . , 1971, Nature: New biology.

[2]  S. Buzzi.  Diphtheria toxin treatment of human advanced cancer. , 1982, Cancer research.

[3]  M. Klagsbrun,et al.  A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF , 1991, Science.

[4]  D. Russell,et al.  Expression cloning of a diphtheria toxin receptor: Identity with a heparin-binding EGF-like growth factor precursor , 1992, Cell.

[5]  M. Klagsbrun,et al.  Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate , 1993, The Journal of cell biology.

[6]  M. Klagsbrun,et al.  Heparin-binding EGF-like growth factor: characterization of rat and mouse cDNA clones, protein domain conservation across species, and transcript expression in tissues. , 1993, Biochemical and biophysical research communications.

[7]  J. Massagué,et al.  Membrane-anchored growth factors. , 1993, Annual review of biochemistry.

[8]  H. Friess,et al.  Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. , 1994, Biochemical and biophysical research communications.

[9]  T. Mitamura,et al.  Heparin‐binding EGF‐like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up‐regulates functional receptors and diphtheria toxin sensitivity. , 1994, The EMBO journal.

[10]  H. Asada,et al.  Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. , 1994, The Journal of biological chemistry.

[11]  M. Klagsbrun,et al.  Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. , 1995, Molecular biology of the cell.

[12]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[13]  S. Yamashita,et al.  Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. , 1995, The Journal of clinical investigation.

[14]  Carmen Birchmeier,et al.  Multiple essential functions of neuregulin in development , 1995, Nature.

[15]  T. Mitamura,et al.  Diphtheria Toxin Binds to the Epidermal Growth Factor (EGF)-like Domain of Human Heparin-binding EGF-like Growth Factor/Diphtheria Toxin Receptor and Inhibits Specifically Its Mitogenic Activity (*) , 1995, The Journal of Biological Chemistry.

[16]  M. Klagsbrun,et al.  Heparin-like Molecules on the Cell Surface Potentiate Binding of Diphtheria Toxin to the Diphtheria Toxin Receptor/Membrane-anchored Heparin-binding Epidermal Growth Factor-like Growth Factor (*) , 1995, The Journal of Biological Chemistry.

[17]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[18]  M. Klagsbrun,et al.  The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor , 1995, The Journal of cell biology.

[19]  E. Mekada,et al.  Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin alpha 3 beta 1 at cell-cell contact sites , 1995, The Journal of cell biology.

[20]  M. Klagsbrun,et al.  Activation of HER4 by heparin‐binding EGF‐like growth factor stimulates chemotaxis but not proliferation , 1997, The EMBO journal.

[21]  M. Klagsbrun,et al.  Heparin-binding EGF-like growth factor. , 1997, Biochimica et biophysica acta.

[22]  K. Mishima,et al.  Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas , 1998, Acta Neuropathologica.

[23]  M. Klagsbrun,et al.  Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin‐binding EGF‐like growth factor independently of protein kinase C , 1998, Journal of cellular biochemistry.

[24]  D. Stern,et al.  Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[25]  M Markman,et al.  Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. , 1998, JAMA.

[26]  P. Vogt,et al.  Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Ullrich,et al.  EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF , 1999, Nature.

[28]  E. Mekada,et al.  Contact-dependent Growth Inhibition and Apoptosis of Epidermal Growth Factor (EGF) Receptor-expressing Cells by the Membrane-anchored Form of Heparin-binding EGF-like Growth Factor* , 1999, The Journal of Biological Chemistry.

[29]  David C. Lee,et al.  Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. , 1999, Development.

[30]  P. A. Harding,et al.  Induction of anchorage independent growth by heparin-binding EGF-like growth factor (HB-EGF). , 1999, Growth factors.

[31]  M. Klagsbrun,et al.  Heparin-binding EGF-like growth factor interacts with mouse blastocysts independently of ErbB1: a possible role for heparan sulfate proteoglycans and ErbB4 in blastocyst implantation. , 1999, Development.

[32]  D. Jayne,et al.  Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases , 2000, British Journal of Cancer.

[33]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[34]  A. Prat,et al.  N‐arginine dibasic convertase is a specific receptor for heparin‐binding EGF‐like growth factor that mediates cell migration , 2001, The EMBO journal.

[35]  S. Poulsen,et al.  A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. , 2001, Cancer research.

[36]  J. Merchant,et al.  ZBP-89, Sp1, and Nuclear Factor-κB Regulate Epithelial Neutrophil-activating Peptide-78 Gene Expression in Caco-2 Human Colonic Epithelial Cells* , 2001, The Journal of Biological Chemistry.

[37]  K. Wakasa,et al.  Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma , 2001, International journal of pancreatology : official journal of the International Association of Pancreatology.

[38]  R. Peek,et al.  cag+ Helicobacter pylori Induce Transactivation of the Epidermal Growth Factor Receptor in AGS Gastric Epithelial Cells* , 2001, The Journal of Biological Chemistry.

[39]  E. Mekada,et al.  Identification of serum factor inducing ectodomain shedding of proHB-EGF and sStudies of noncleavable mutants of proHB-EGF. , 2001, Biochemical and biophysical research communications.

[40]  M. Monden,et al.  Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. , 2001, Oncology reports.

[41]  E. Mekada,et al.  A Dual Signaling Cascade That Regulates the Ectodomain Shedding of Heparin-binding Epidermal Growth Factor-like Growth Factor* , 2001, The Journal of Biological Chemistry.

[42]  M. Freeman,et al.  BAG-1 Is a Novel Cytoplasmic Binding Partner of the Membrane Form of Heparin-binding EGF-like Growth Factor , 2001, The Journal of Biological Chemistry.

[43]  S. Dey,et al.  Pre-eclampsia and expression of heparin-binding EGF-like growth factor , 2002, The Lancet.

[44]  J. D. Vos,et al.  Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells , 2002, Oncogene.

[45]  M. Klagsbrun,et al.  The Membrane Protein CD 9 / DRAP 27 Potentiates the Juxtacrine Growth Factor Activity of the Membrane-anchored Heparin-binding EGF-like Growth Factor , 2002 .

[46]  Helmut Burtscher,et al.  Identification of rat pancreatic carcinoma genes associated with lymphogenous metastasis. , 2002, Anticancer research.

[47]  A. Mammoto,et al.  Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) , 2002, Journal of cellular physiology.

[48]  A. Ullrich,et al.  Helicobacter pylori-stimulated EGF receptor transactivation requires metalloprotease cleavage of HB-EGF. , 2002, Biochemical and biophysical research communications.

[49]  Masatsugu Hori,et al.  Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Washington,et al.  Overexpression of heparin-binding EGF-like growth factor in mouse pancreas results in fibrosis and epithelial metaplasia. , 2003, Gastroenterology.

[51]  David C. Lee,et al.  Defective valvulogenesis in HB‐EGF and TACE‐null mice is associated with aberrant BMP signaling , 2003, The EMBO journal.

[52]  A. Mammoto,et al.  Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF , 2003, The Journal of cell biology.

[53]  E. Mekada,et al.  The Stress- and Inflammatory Cytokine-induced Ectodomain Shedding of Heparin-binding Epidermal Growth Factor-like Growth Factor Is Mediated by p38 MAPK, Distinct from the 12-O-Tetradecanoylphorbol-13-acetate- and Lysophosphatidic Acid-induced Signaling Cascades* , 2003, The Journal of Biological Chemistry.

[54]  Y. Kaneda,et al.  Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities , 2003, The Journal of cell biology.

[55]  M. Fujimoto,et al.  Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Kai,et al.  Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy , 2004, Cancer Research.

[57]  Y. Yarden,et al.  Oncogenic growth factor receptors: implications for signal transduction therapy. , 2004, Seminars in cancer biology.

[58]  R. Romero,et al.  Heparin-binding EGF-like growth factor regulates human extravillous cytotrophoblast development during conversion to the invasive phenotype. , 2004, Developmental biology.

[59]  Joseph Schlessinger,et al.  Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors , 2004, Science.

[60]  C. Morisi,et al.  CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients , 2004, Cancer Immunology, Immunotherapy.

[61]  M. Romano,et al.  Helicobacter pyloriγ‐glutamyltranspeptidase upregulates COX‐2 and EGF‐related peptide expression in human gastric cells , 2004, Cellular microbiology.

[62]  A. Ullrich,et al.  Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion , 2004, Oncogene.

[63]  P. Ongusaha,et al.  HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis , 2004, Cancer Research.

[64]  R. Harris,et al.  Membrane-associated HB-EGF modulates HGF-induced cellular responses in MDCK cells , 2004, Journal of Cell Science.

[65]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[66]  E. Mekada,et al.  HB-EGF promotes epithelial cell migration in eyelid development , 2005, Development.

[67]  E. Mekada,et al.  Soluble form of heparin-binding EGF-like growth factor contributes to retinoic acid-induced epidermal hyperplasia. , 2005, Cell structure and function.

[68]  T. Joh,et al.  IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. , 2005, Cytokine.

[69]  S. Miyamoto,et al.  Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer , 2005, British Journal of Cancer.

[70]  Satoshi O. Suzuki,et al.  Clinical Significance of Heparin-Binding Epidermal Growth Factor–Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer , 2005, Clinical Cancer Research.

[71]  E. Mekada,et al.  Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing , 2005, Journal of Cell Science.

[72]  E. Mekada,et al.  Cytoplasmic domain phosphorylation of heparin-binding EGF-like growth factor. , 2006, Cell structure and function.

[73]  F. Khuri,et al.  Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. , 2006, Oncology.

[74]  Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer , 2007 .